[Tachythymoanaleptic action of Melitracene: indication in reactive depressions and neurotic inhbitions (272 cases)].
D000275:Adjustment Disorders / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007266:Inhibition, Psychological; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D013610:Tachycardia / Q000139:chemically induced*
D000873:Anthracenes; D000928:Antidepressive Agents; D011437:Propylamines
Pouvoir tachythymanaleptique du mélitracène: indication dans les dépressions réactionnelles et les inhbitions névrotiques (272 cas.